Catherine Torralva
Family · San Antonio, TXNPI 1760854178
Payments from drug & device makers
Across 357 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- Novartis$1K
- Lilly USA, LLC$779
- UCB, Inc.$643
- Mallinckrodt Hospital Products Inc.$616
- plus $2K from 17 others
What the payments were for
- Food & beverage$8,30798%
- Education$2002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 87 | $1,869 |
| Johnson & Johnson | 54 | $1,361 |
| Novartis | 47 | $1,044 |
| Lilly USA, LLC | 28 | $779 |
| UCB, Inc. | 19 | $643 |
| Mallinckrodt Hospital Products Inc. | 25 | $616 |
| AstraZeneca | 27 | $509 |
| AbbVie | 5 | $392 |
| GSK | 14 | $319 |
| Pfizer | 13 | $212 |
| Fresenius Kabi USA, LLC | 6 | $160 |
| Genentech USA, Inc. | 9 | $153 |
| E.r. Squibb & Sons, L.L.C. | 6 | $124 |
| Ferring Pharmaceuticals Inc. | 4 | $58 |
| Radius Health, Inc. | 3 | $55 |
| Octapharma USA, Inc. | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $32 |
| Celltrion USA Inc. | 1 | $31 |
| Invivyd Inc | 1 | $24 |
| Sandoz | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,507 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 17 | $146,848 |
| Hydroxychloroquine Sulfate | 106 | $4,196 |
| Leflunomide | 52 | $3,719 |
| MethotrexateMethotrexate Sodium | 104 | $3,640 |
| Sulfasalazine DrSulfasalazine | 33 | $2,391 |
| Mycophenolate Mofetil | 15 | $1,600 |
| Duloxetine Hcl | 32 | $1,009 |
| Colchicine | 12 | $986 |
| Sulfasalazine | 18 | $468 |
| Gabapentin | 24 | $422 |
| Methylprednisolone | 58 | $359 |
| Prednisone | 56 | $232 |
| Folic Acid | 26 | $229 |
| Meloxicam | 22 | $161 |
| Allopurinol | 17 | $158 |
Paid to pharmacies, not to this prescriber.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.